(Q33918113)

30 July 2017

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma (English)

1 reference

30 July 2017

A Patnaik

1

1 reference

30 July 2017

G J Weiss

2

1 reference

30 July 2017

K P Papadopoulos

3

1 reference

30 July 2017

C C Hofmeister

4

1 reference

30 July 2017

R Tibes

5

1 reference

30 July 2017

A Tolcher

6

1 reference

30 July 2017

R Isaacs

7

1 reference

30 July 2017

J Jac

8

1 reference

30 July 2017

M Han

9

1 reference

30 July 2017

F C Payumo

10

1 reference

30 July 2017

M M Cotreau

11

1 reference

30 July 2017

R K Ramanathan

12

1 reference

30 July 2017

language of work or name

English

0 references

publication date

5 June 2014

1 reference

British Journal of Cancer

30 July 2017

1 reference

30 July 2017

111

1 reference

30 July 2017

2

1 reference

30 July 2017

272-280

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2014.290

30 July 2017

0 references

cites work

Targeting MET in cancer: rationale and progress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Drug development of MET inhibitors: targeting oncogene addiction and expedience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Showering c-MET-dependent cancers with drugs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Signaling networks assembled by oncogenic EGFR and c-Met

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Comparing antibody and small-molecule therapies for cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

International uniform response criteria for multiple myeloma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Met, metastasis, motility and more

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Design and analysis of phase I clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.

5 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.290

Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.290

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.290

Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.290

Met decoys: will cancer take the bait?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.290

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.290

The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4102944

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV

29 October 2018

1 reference

12 December 2020

Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer

1 reference

12 December 2020

Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma

1 reference

12 December 2020

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2014.290

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference